Cronfa - Swansea University Open Access Repository

This is an author produced version of a paper published in:
Placenta

Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa34833

Paper:
Bryant, A., Bevan, R., Spencer-Harty, S., Scott, L., Jones, R. & Thornton, C. (2017). Expression and function of NOD-like receptors by human term gestation-associated tissues. *Placenta, 58*, 25-32.
http://dx.doi.org/10.1016/j.placenta.2017.07.017

Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).

This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior permission for personal research or study, educational or non-commercial purposes only. The copyright for any work remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium without the formal permission of the copyright holder.

Permission for multiple reproductions should be obtained from the original author.

Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the repository.

http://www.swansea.ac.uk/library/researchsupport/ris-support/

1 **Title:** Expression and function of NOD-like receptors by human term gestation-associated tissues

2

3 **Short title:** NLRs at the materno-fetal interface

4

5 **Authors:** Aled H Bryant[1], Ryan J Bevan[1], Samantha Spencer-Harty[2], Louis M Scott[1], Ruth H Jones[1],

6 Catherine A Thornton[1,3]

7

8 [1] Institute of Life Science, Swansea University Medical School, Swansea, Wales, UK

9 [2] Histopathology Department, Singleton Hospital, Abertawe Bro Morgannwg University Health

10 Board, Swansea, Wales, UK

11 [3] Corresponding Author: Professor Cathy Thornton

12 E-mail c.a.thornton@swansea.ac.uk, Telephone: 01792 602122.

13

14

15

16

17

18

19

20 **Abstract**

21 **Introduction:** Nucleotide-binding oligomerization domain (NOD)-like receptors or NOD-like

22 receptors (NLRs) have been implicated in several disease pathologies associated with inflammation.

23 Since local and systemic inflammation is a hallmark of both term and preterm labour, a role for NLRs
24 at the materno-fetal interface has been postulated.

25 **Methods:** Gene expression and immunolocalisation of NLR family members in human placenta,
26 choriodecidua, and amnion were examined. Tissue explants were used to examine the response to
27 activators of NOD1 (Tri-DAP), NOD2 (MDP) and NLRP3 (nigericin). Cell/tissue-free supernatants
28 were examined for the production of interleukin (IL)-1β, IL-6, IL-8 and IL-10 using specific ELISAs.

29 **Results:** Expression of transcripts for *NOD1*, *NOD2*, *NLRP3*, *NLRC4*, *NLRX1*, *NLRP1* and *NAIP* and
30 protein expression of NOD1, NOD2 and NLRP3 were a broad feature of all term gestation-associated
31 tissues. Production of cytokines was increased significantly in response to all ligands in placenta and
32 choriodecidua, except for MDP-induced IL-10. Similarly, there was a significant increase in cytokine
33 production in the amnion except for MDP induced IL-1β and IL-10 response to either agonist. IL-1β
34 production was dependent on caspase-1 regardless of agonist used or tissue examined.

35 **Discussion:** Term human gestation-associated tissues express functional NLRs which likely play a
36 role in both sterile and pathogen-driven inflammatory responses at the materno-fetal interface.

37

38

39

40 **Keywords:** Inflammation; reproductive immunology; preterm labour; NOD-like receptors

41

42 **Abbreviations:** DAMP, damage associated molecular pattern; ECS, elective caesarean section; LPS,
43 lipopolysaccharide; IL-, interleukin; MDP, muramyl dipeptide; NLR, NOD-like receptors; NOD,
44 nucleotide-binding oligomerisation domain**;** PAMPs, pathogen associated molecular patterns; PRR,
45 pattern recognition receptor; TLR, toll-like receptor; Tri-DAP, L-Ala-γ-D-Glu-mDAP.

46

47

Introduction

Nucleotide-binding oligomerization domain-like receptors, or NOD-like receptors (NLRs), are a family of intracellular pattern recognition receptors (PRRs). They are involved in the recognition of both pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) that have entered the cell [1]. Numerous NLRs have been described and they are divided into five subfamilies based on their N-terminal domain [1]. The first identified and most widely studied NLRs are NOD1 and NOD2 [2]. NOD1 and NOD2 recognise structures within bacterial peptidoglycan; NOD1 recognises iE-DAP and Tri-DAP specific to Gram-negative bacteria, whereas NOD recognises MDP, common to both Gram-negative and -positive bacteria [2]. Certain members of the NLR family, including NLRP1 and NLRP3, following the detection of PAMPs or DAMPs trigger the assembly of a large caspase 1 activating complex termed the inflammasome which enables the processing and secretion of pro-forms of IL-1β and IL-18 [3].

Preterm birth (PTB) is the leading cause of perinatal morbidity and mortality in the Western world. Intrauterine infection is a common mechanism of preterm labour but the role of damage in this pathology is becoming increasingly apparent [4]. As the common outcome of both PAMP and DAMP signals is local and systemic inflammation, a role for PRRs in the pathophysiology of preterm labour and birth has long been suggested [5]. It is increasingly apparent that NLRs play a role in several disease pathologies associated with inflammation [6,7] so a role for NLRs in preterm labour and other adverse pregnancy outcomes would not be unexpected.

NOD1 and NOD2 expression by term human decidua and only NOD1 expression in term amnion epithelial cells have been reported [8]. Functionally, NOD1 and NOD2 activity have been observed in total fetal membrane explants [9], but NLR activity by separated amnion and choriodecidua has not been examined to date. For the placenta, NOD1 but not NOD2 has been reported as expressed and functional in term trophoblast cells, whereas in first trimester placental trophoblast both NOD2 and

74 NOD1 are expressed with corresponding functional output [10]. However, several other cell
75 populations are present within the placenta that would likely contribute to the inflammatory profile of
76 this organ. Expression of transcripts for NLRP3 by first trimester placenta has been observed [11],
77 and a functional response in the first trimester trophoblast cell line Sw.71 and term cytotrophoblasts to
78 uric acid, a NLRP3 activator, has also been noted [12-14]. Term fetal membranes show expression of
79 NLRP3 with a functional response observed in explants treated with the NLRP3 activators ATP and
80 nigericin [15].

81

82 Our objective was to increase understanding of the possible role of NLRs in a reproductive setting by
83 examining the expression and functional activity of the NLRs simultaneously in term placenta,
84 choriodecidua and amnion. Where possible, functional activity was examined using an explant model
85 to better mimic the cellular heterogeneity that occurs *in utero*.

86

87

88

89

90

91

92

93

94

Materials and Methods

Samples

Placenta and fetal membrane samples were collected from healthy term newborns (>37 weeks of gestation) delivered by elective caesarean section at Singleton Hospital, Swansea, UK. Informed, written consent was obtained from all study participants following recruitment at the antenatal day assessment unit. Ethical approval for this study was given by Wales Research Ethics Committee 6 (REC No. 11/WA/0040).

Explant Cultures

Placenta. Placental explant cultures were prepared as described previously [16,17]. Briefly, the overlaying decidua basalis of the maternal side of the placenta was removed and 1 cm^3 pieces of placenta tissue were cut from various sites and placed into sterile calcium and magnesium free phosphate buffered saline (PBS; Life Technologies, UK). Tissue was washed repeatedly with PBS to remove contaminating blood. Tissue was then minced into smaller pieces and washed further. Pieces of tissue (1mm^3 pieces to a total of 0.2 g) were cultured in UltraCULTURE medium (Lonza, Switzerland), supplemented with 2 mM GlutaMAX (Life Technologies, UK) and 2 mM penicillin, streptomycin, Fungizone (PSF; Life Technologies, UK).

Membranes. Membranes were detached from the placenta. Choriodecidua and amnion were separated from each other by blunt dissection and placed individually into PBS. Tissue was washed repeatedly with PBS to remove any contaminating blood. Each membrane was cut with an 8mm biopsy punch (Stiefel, Medisave, UK). Two biopsies of choriodecidua were cultured in 0.5 ml of Advanced RPMI (Life Technologies, UK) supplemented with 2 mM GlutaMAX, 2% FBS (HyClone; Thermo Fisher Scientific, UK) 2 mM PSF and 5mM 2-mercaptoethanol (2-ME; Thermo Fisher Scientific). Three

119 biopsies of amnion were cultured in 0.5 ml of Advanced DMEM (Life Technologies, UK)
120 supplemented with 2 mM GlutaMAX, 2% FBS and 2 mM PSF.

121

122 Once prepared, explant cultures were exposed to different stimuli with an unstimulated control always
123 included. Optimal levels of all agonists were determined by dose course experiments on gestation-
124 associated tissues explants and the following final concentrations were used; Tri-DAP (NOD1, 10
125 μg/ml), MDP (NOD2, 10 μg/ml), LPS (10 ng/ml) and nigericin (1μM) (all from Invivogen, USA).
126 For inhibition experiments, cultures were treated with an inhibitor of caspase-1 (Z-WEHD-FMK, 5
127 μM; R&D systems) 30 min before the addition of Tri-DAP, MDP or nigericin. Cellular cytotoxicity
128 was not observed with addition of inhibitors (data not shown) as determined by lactate dehydrogenase
129 assay (Abcam). All treatments were performed in duplicate. Cultures were incubated for 24 hours at
130 37°C in 5% CO_2. Tissue free supernatants were collected by centrifugation for 7 minutes at 4°C, 515
131 x g and stored at -20°C for analysis using cytokine specific ELISAs.

132

133 *Cytokine production*

134 Levels of IL-1β, IL-6, IL-8 and IL-10 in tissue free supernatants of placenta, choriodecidua and
135 amnion explant cultures collected after 24 h were measured using commercially available ELISA kits
136 (DuoSet, R&D Systems) as per manufacturer's instructions.

137

138 *RNA Extraction from Gestation-Associated Tissue Samples*

139 Biopsies of tissue were preserved in TRI reagent (Sigma-Aldrich, UK) at -20°C. DNA-free RNA was
140 prepared from homogenised tissue (FastPrep FP120A Homogeniser; Qbiogene, The Netherlands)
141 following the TRIzol method of extraction and DNA-free DNase kit (Ambion®, Thermo Fisher
142 Scientific, UK) as per manufacturer's instructions. Purity and concentration of RNA were measured
143 (NanoDrop 3300 flurospectrometer; NanoDrop Technologies, USA).

144

145 *Polymerase Chain Reaction (PCR)*

146 Reverse transcription was performed using the RETROscript kit (Ambion®, Thermo Fisher
147 Scientific, UK) as per manufacturer's instructions. Polymerase chain reaction was performed using
148 the Platinum® Taq DNA Polymerase kit and dNTP Mix (both Thermo Fisher Scientific, UK). All
149 primers were synthesised by Thermo Fisher Scientific, using sequences obtained using primer BLAST
150 (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). *UBE2D2* housekeeping primers were based on
151 previously published sequences [18]. Primer sequences and specific conditions for each PCR are
152 listed in Table 1.

153

154 *Immunohistochemistry*

155 Immunohistochemical staining for NOD1, NOD2 and NLRP3 was performed on formalin fixed,
156 paraffin embedded sections (4 µm) of placenta and fetal membranes using the Ventana ULTRA
157 automated staining instrument as described previously (24). The following modifications were made:
158 Optiview detection system was used without A/B blocker or amplification, antigen retrieval was
159 carried out in CC1 buffer for 16 minutes for both NOD1 and NLRP3, and in protease 1 for 8 minutes
160 for NOD2. Mouse monoclonal anti-NOD1 (10 µg/ml; R&D Systems, USA), rabbit polyclonal anti-
161 NOD2 (3 µg/ml; LifeSpan BioSciences, Inc, USA) and mouse monoclonal anti-NLRP3 (10 µg/ml;
162 Abcam, USA) were incubated at 36°C for 40, 24 and 36 minutes, respectively. For control slides,
163 primary antibody was replaced with either rabbit IgG (3 µg/ml; Biolegend), mouse IgG1 (10 µg/ml;
164 eBioscience), or mouse IgG2b (10 µg/ml; eBioscience) isotype controls at the same concentration.

165

166 *Data analysis*

167 All experiments were performed a minimum of three times. Cytokine production by non-laboured
168 tissues was evaluated using repeated measures one-way ANOVA with Dunnett's multiple comparison

169 test. A *p*-value of ≤ 0.05 was considered significant. Statistical significance was calculated using
170 GraphPad Prism (Version 6, GraphPad Software Inc, USA).

171

172

173

174

175

176

177

178 **Results**

179 **Expression of transcripts of NLRs by gestation-associated tissues**

180 PCR analysis revealed expression of transcripts for *NOD1*, *NOD2*, *NLRP3*, *NLRC4*, *NLRX1*, *NLRP1*
181 and *NAIP* in all gestation-associated tissues studied. PCR was performed using five individual
182 samples of each tissue type (placenta, choriodecidua and amnion); three of these five samples are
183 shown (Figure 1). Transcripts for each NLR examined were present in all five samples of each of the
184 tissues.

185

186 **Immunolocalisation and function of NOD1 and NOD2 by gestation-associated tissues**

187 Expression of NOD1 and NOD2 was examined using immunohistochemistry (Figure 2A). In the
188 placenta, expression of NOD1 was localised to the syncytiotrophoblast, while NOD2 expression was
189 present in the syncytiotrophoblast and cells within the stroma. In the fetal membranes both NOD1 and
190 NOD2 expression were present in the amnion epithelial cells, chorionic trophoblast and cells within
191 the decidua. This expression pattern was similar for all 7 samples studied.

192

193 To investigate if NOD1 and NOD2 were functional, the agonists L-Ala-γ-D-Glu-mDAP (Tri-DAP;
194 NOD1, 10 μg/ml) and muramyl dipeptide (MDP; NOD2, 10 μg/ml) were used. Both Tri-DAP and
195 MDP induced a significant increase in IL-1β, IL-6, IL-8 and IL-10 by the placenta (Figure 3A). A
196 significant increase in both IL-6 and IL-8 in response to NOD1 and NOD2 activation also was a
197 common feature of both the choriodecidua and amnion (Figure 3B and C). Both Tri-DAP and MDP
198 induced significant IL-1β by choriodecidua, however only Tri-DAP induced a significant IL-10
199 response (Figure 3C). With regards to the amnion, treatment with Tri-DAP induced significant IL-1β
200 and IL-10, however MDP did not induce IL-1β above background and there was no significant effect
201 on IL-10 production (Figure 3C).

202

203 **Immunolocalisation and function of NLRP3 by gestation-associated tissues**

204 NLRP3 expression was examined using immunohistochemistry (Figure 4A). In the placenta,
205 expression of NLRP3 was localised primarily to syncytiotrophoblast and cells within the stroma. In
206 the fetal membranes, NLRP3 was expressed by the chorionic trophoblast, cells within the decidua and
207 amnion epithelial cells. For all tissues NLRP3 reactivity appeared to be localised to the nucleus.
208 Tissue samples from seven different donors were studied and all were positive for NLRP3. However,
209 while there was little variability in intensity of NLRP3 reactivity within the fetal membranes there
210 were noticeable differences in the placenta and this seems to be inversely correlated to maternal BMI
211 (Supplementary Figure 1).

212

213 To investigate if the NLRP3 inflammasome was functional, the potassium ionophore nigericin (1μM)
214 derived from *Streptomyces hygroscopicus* was used. Prior to the addition of nigericin tissue explants
215 were primed with LPS (10 ng/ml) for 3 hours. A significant increase in IL-1β, above both background
216 and LPS treatment alone, was observed for each tissue following exposure to nigericin (Figure 4B-D).

217

218 **NLR induced IL-1β production is caspase-1 dependent**

219 As the production and secretion of IL-1β following NLRP3 activation is reliant on caspase-1, a
220 caspase-1 inhibitor was utilized to confirm the involvement of the NLRP3 inflammasome. This
221 approach was also applied to explants treated with both Tri-DAP and MDP due to the robust IL-1β
222 response observed. In the presence of capase-1 inhibitor, both Tri-DAP- and MDP-induced IL-1β
223 levels were inhibited in the placenta (Figure 5A), choriodecidua (Figure 5B) and amnion (Tri-DAP
224 only; Figure 5C). A decrease in IL-1β in the presence of capase-1 inhibitor was also observed for
225 treatment with both LPS alone and LPS and nigericin in all tissues examined (Figure 5D-F).

226

227

228

229

230

231

232

233

234

235

236

237

238 **Discussion**

239 Inflammation caused by infection or damage is a common feature of various pathologies [4] and
240 NLRs have been implicated to have a role. Since a hallmark of both term and preterm labour is local
241 and systemic inflammation a role for NLRs at the materno-fetal interface has been postulated [5].
242 Here we demonstrate that specific agonists for the NLRs - NOD1, NOD2 and NLRP3 - generate
243 cytokine production by the placenta, choriodecidua and amnion, corresponding to expression at both
244 the gene and protein level. Additionally, expression of transcripts of other NLRs, namely NLRC4,
245 NLRX1, NLRP1 and NAIP by term gestation-associated tissues been demonstrated for the first time.

246

247 Previous investigations of NOD expression by the placenta have been limited to primary first and
248 third trimester trophoblast. Transcripts and protein for both NOD1 and NOD2 were found in first
249 trimester trophoblast but only for NOD1 in third trimester trophoblast with a corresponding functional
250 response [19,20]. Here we demonstrate that transcripts and protein for both NOD1 and NOD2 are
251 present in the term placenta. Furthermore, treatment of placental explants with Tri-DAP (NOD1) and
252 MDP (NOD2) resulted in increased cytokine production (IL-1β, IL-6, IL-8 and IL-10) implying that
253 both receptors are functional. Increases in pro-inflammatory cytokines are not unexpected as both Tri-
254 DAP and MDP are known initiators of inflammation. The increase in the anti-inflammatory cytokine
255 IL-10 might represent a compensatory mechanism: concentrations of anti-inflammatory cytokines are
256 increased in the amniotic fluid from women who delivered preterm and had evidence of intra-
257 amniotic infection [21] possibly representing a failed compensatory mechanism [22]. Discrepancies
258 in NOD2 expression and function might be related to the model of investigation used, i.e. a
259 dissociated cell culture model focussing on trophoblast only [19,20] in comparison to explants as
260 here. The placenta is heterogeneous, composed of many cell types such as cytotrophoblast,
261 syncytiotrophoblast, mesenchymal stem cells, endothelial cells and macrophages (Hofbauer cells). It
262 is possible that other non-trophoblast cell types within the placenta are responsible for both NOD2
263 expression and activity as observed by us. For example, both monocyte derived macrophages
264 (MDMs) [23] and tissue-resident macrophages [24,25] express NOD2 in humans.
265 Immunohistochemistry of NOD1 and NOD2 expression revealed this to be the case. NOD1

266 expression within the placenta was localised to syncytiotrophoblast cells while NOD2 was expressed
267 in both syncytiotrophoblast and other cells within the stroma. This observation of NOD2 expression
268 by trophoblast cells of the term placenta clearly differs from previous reports where the MDP-
269 stimulated IL-8 response in term cytotrophoblast lacking NOD2 expression was described as NOD2-
270 independent [19].

271

272 MDP can also activate human NLRP1 [26] which is involved primarily in inflammasome activity
273 typically measured via IL-1β output. Transcripts for NLRP1 have been reported in first trimester
274 trophoblast in addition to decidual stroma and endothelial cells [11]. We found transcripts for both
275 NLRP1 as well as other inflammasome-associated NLRs, namely NLRP3, NLRC4 and NAIP, in the
276 term placenta. MDP was also able to induce IL-1β production in the placenta in a caspase-1 dependent
277 manner. IL-1β production by MDP treated trophoblasts, either first or third trimester, has not been
278 reported [10,19] and since transcripts for NLRP1 are present, it is possible that the NOD2-
279 independent IL-8 observed [27,28] might relate to autocrine exposure to IL-1β.

280

281 NOD1 and NOD2 expression and responsiveness have been reported in the fetal membranes with
282 NOD1 and NOD2 protein expressed by chorionic cytotrophoblasts and decidual cells but only NOD1
283 by amnion epithelial cells; both receptors were up-regulated following spontaneous labour [8]. In
284 contrast, we found NOD1 and NOD2 protein expression using immunohistochemistry in cells of the
285 amnion, chorion and decidua. Term choriodecidua and amnion both produced IL-6 and IL-8 in
286 response to Tri-DAP and MDP treatment, corresponding to term fetal membrane explants treated with
287 iE-DAP (NOD1) and MDP [8]. Additionally, we demonstrated that the choriodecidua produces IL-1β
288 in response to both Tri-DAP and MDP, and IL-10 in response to Tri-DAP. The amnion produced IL-
289 1β in response to Tri-DAP treatment, while neither Tri-DAP nor MDP treatment resulted in a
290 significant IL-10 response. The caspase-1 dependence of Tri-DAP and/or MDP IL-1β production by
291 the choriodecidua and amnion was confirmed. The balance of pro and anti-inflammatory cytokines

292 observed in the choriodecidua, mimics that of the placenta, suggesting a similar functional activity of
293 NLRs in these tissues. However, while the amnion has both functional NOD2 and NLRP3 and active
294 caspase-1, its unknown why activation with MDP does not result in an IL-1β response. MDP induced
295 IL-1β might require the activity of other initiator caspases in the amnion.

296

297 NLRP3 expression in term placenta was localised primarily to the syncytiotrophoblast in keeping with
298 the observation of NLRP3 gene expression by first trimester trophoblasts [11]. NLRP3 expression
299 was noted in all samples studied but there was variability in this. NLRP3 expression and subsequent
300 inflammasome activation can be affected by several different factors including smoking status [30],
301 obesity [31] and age [32]. In our study, the expression of placental NLRP3 seemed to correlate
302 negatively with BMI, i.e. decreasing NLRP3 expression with increasing maternal BMI. This contrasts
303 with a previously published report of a positive correlation of trophoblast produced IL-1β with
304 maternal BMI, though caspase-1 signalling was unaffected [33]. However, with only seven samples
305 included in our study, caution should be taken until more samples can be examined (supplementary
306 figure 1). Expression of NLRP3 was also observed by both the amnion and choriodecidua, however
307 unlike the placenta, expression of NLRP3 was constant between donors. This observation of NLRP3
308 expression is in keeping previous reports [35] but we noted that NLRP3 expression was
309 predominantly nuclear. While typically considered a cytoplasmic protein, NLRP3 has been shown to
310 function as a nuclear transcription factor, positively regulating Th2 immunity, independent of
311 inflammasome activity [36]. Nuclear translocation of NLRP3 might have a role in placental regulation
312 of the Th2 predominance in pregnancy [37]. With a negative correlation between placental NLRP3
313 expression and maternal BMI, the loss of a NLRP3 driven Th2 environment might explain the
314 increased inflammatory environment in obese pregnant women and the associated risk of adverse
315 pregnancy outcomes [34].

316

317 Activation of the NLRP3 inflammasome by DAMPs, such as uric acid crystals or ATP, is associated
318 with a "two-step" mode of activation [3]. Here functional placental NLRP3 is shown using an LPS
319 prime (signal 1) and the potassium ionophore nigericin (signal 2) to give a significant increase in the
320 production of IL-1β in a caspase-1 dependent manner. Previous studies have produced an IL-1β
321 response in the first trimester trophoblast cell line Sw.71 [12,13] and term cytotrophoblasts [14] using
322 uric acid crystals, although no priming signal was used in these studies. Caspase-1 dependent IL-1β
323 production in response to nigericin was also observed by the choriodecidua and amnion,
324 corresponding to IL-1β production by fetal membrane explants in response to ATP treatment [15,38].

325

326 In addition to NOD1, NOD2 and NLRP3, we have also shown that term placenta, choriodecidua and
327 amnion express transcripts for NLRC4, NLRX1, NLRP1, and NAIP. Gene expression of NLRP1 and
328 NAIP by the placenta [39] and gene and protein expression of NRLP1 and NLRC4 by term fetal
329 membranes [35] has been reported by others. This is however the first report of placental NLRC4,
330 fetal membranes NAIP expression, and NLRX1 expression by all three gestation-associated tissues.
331 Furthermore while we have focussed on the casapase-1 dependence of IL-1β production, several other
332 caspases (caspase-4, -5, -8 and -12) can either directly, by canonical and non-canonical
333 inflammasomes, or indirectly modulate the production of IL-1β [40]. Functional activity of these
334 NLRs and other caspases by gestation-associated tissues is still to be examined with our recent work
335 showing a contribution of Caspases-1, -4 and -8 to IL-1β production in placenta, choriodecidua and
336 amnion (Scott et al. Cytokine. Accepted).

337

338 The role of NLRs, especially through the production of IL-1β, highlights a potential role for this
339 family of PRRs in the inflammation that occurs with preterm birth [41]. This inflammation can be
340 driven by PAMPs or DAMPs but has common downstream outcomes related to chorioamnionitis,
341 fetal membrane rupture, cervical ripening, and parturition [5,41]. Better understanding of the
342 expression and activity of NLRs in adverse pregnancy outcomes is now required.

343

344 **Acknowledgements**

345 Funding for this research was provided by Health and Care Research Wales. We are grateful to all the
346 staff in the antenatal day assessment unit and on the delivery suite at Singleton Hospital Swansea for
347 their tireless help in the collection of samples. Thank you also to all the women who agreed to the use
348 of their placentas for this study.

349

350

351

352 **References**

353

354 1 Kim YK, Shin J-S, Nahm MH: Nod-like receptors in infection, immunity, and diseases. Yonsei
355 Medical Journal 2016;57:5-14.

356 2 Moreira LO, Zamboni DS: Nod1 and nod2 signaling in infection and inflammation. Front
357 Immunol 2012;3:328.

358 3 Guo H, Callaway JB, Ting JPY: Inflammasomes: Mechanism of action, role in disease, and
359 therapeutics. Nat Med 2015;21:677-687.

360 4 Nadeau HCG, Subramaniam A, Andrews WW: Infection and preterm birth. Seminars in Fetal
361 and Neonatal Medicine 2016;21:100-105.

362 5 Bryant AH, Thornton CA: Cytokines and the innate immune response at the materno-fetal
363 interface. INTECH Open Access Publisher, 2012.

364 6 McGettrick AF, O'Neill LA: Nlrp3 and il-1beta in macrophages as critical regulators of
365 metabolic diseases. Diabetes Obes Metab 2013;15 Suppl 3:19-25.

366 7 Le Bourhis L, Benko S, Girardin SE: Nod1 and nod2 in innate immunity and human
367 inflammatory disorders. Biochem Soc Trans 2007;35:1479-1484.

368 8 Lappas M: Nod1 and nod2 regulate proinflammatory and prolabor mediators in human fetal
369 membranes and myometrium via nuclear factor-kappa b. Biol Reprod 2013;89:14.

370 9 Hoang M, Potter JA, Gysler SM, Han CS, Guller S, Norwitz ER, Abrahams VM: Human fetal
371 membranes generate distinct cytokine profiles in response to bacterial toll-like receptor and nod-like
372 receptor agonists. Biol Reprod 2014;90:39.

373 10 Costello MJ, Joyce SK, Abrahams VM: Nod protein expression and function in first trimester
374 trophoblast cells. Am J Reprod Immunol 2007;57:67-80.

375 11 Pontillo A, Girardelli M, Agostinis C, Masat E, Bulla R, Crovella S: Bacterial lps differently
376 modulates inflammasome gene expression and il-1beta secretion in trophoblast cells, decidual
377 stromal cells, and decidual endothelial cells. Reprod Sci 2012

378 12 Mulla MJ, Myrtolli K, Potter J, Boeras C, Kavathas PB, Sfakianaki AK, Tadesse S, Norwitz ER,
379 Guller S, Abrahams VM: Uric acid induces trophoblast il-1beta production via the inflammasome:
380 Implications for the pathogenesis of preeclampsia. Am J Reprod Immunol 2011;65:542-548.

381 13 Mulla MJ, Salmon JE, Chamley LW, Brosens JJ, Boeras CM, Kavathas PB, Abrahams VM: A
382 role for uric acid and the nalp3 inflammasome in antiphospholipid antibody-induced il-1beta
383 production by human first trimester trophoblast. PLoS One 2013;8:e65237.

384 14 Brien ME, Duval C, Palacios J, Boufaied I, Hudon-Thibeault AA, Nadeau-Vallee M, Vaillancourt
385 C, Sibley CP, Abrahams VM, Jones RL, Girard S: Uric acid crystals induce placental inflammation and
386 alter trophoblast function via an il-1-dependent pathway: Implications for fetal growth restriction. J
387 Immunol 2017;198:443-451.

388 15 Lappas M: Caspase-1 activation is increased with human labour in foetal membranes and
389 myometrium and mediates infection-induced interleukin-1β secretion. American Journal of
390 Reproductive Immunology 2014;71:189-201.

391 16 Patni S, Bryant AH, Wynen LP, Seager AL, Morgan G, Thornton CA: Functional activity but not
392 gene expression of toll-like receptors is decreased in the preterm versus term human placenta.
393 Placenta 2015;36:1031-1038.

394 17 Patni S, Wynen LP, Seager AL, Morgan G, White JO, Thornton CA: Expression and activity of
395 toll-like receptors 1-9 in the human term placenta and changes associated with labor at term. Biol
396 Reprod 2009;80:243-248.

397 18 Popov N, Schulein C, Jaenicke LA, Eilers M: Ubiquitylation of the amino terminus of myc by
398 scf(beta-trcp) antagonizes scf(fbw7)-mediated turnover. Nat Cell Biol 2010;12:973-981.

399 19 Cardenas I, Mulla MJ, Myrtolli K, Sfakianaki AK, Norwitz ER, Tadesse S, Guller S, Abrahams
400 VM: Nod1 activation by bacterial ie-dap induces maternal-fetal inflammation and preterm labor. J
401 Immunol 2011;187:980-986.

402 20 Abrahams VM: The role of the nod-like receptor family in trophoblast innate immune
403 responses. J Reprod Immunol 2011;88:112-117.

404 21 Gotsch F, Romero R, Kusanovic JP, Erez O, Espinoza J, Kim CJ, Vaisbuch E, Than NG, Mazaki-
405 Tovi S, Chaiworapongsa T, Mazor M, Yoon BH, Edwin S, Gomez R, Mittal P, Hassan SS, Sharma S: The
406 anti-inflammatory limb of the immune response in preterm labor, intra-amniotic
407 infection/inflammation, and spontaneous parturition at term: A role for interleukin-10. J Matern
408 Fetal Neonatal Med 2008;21:529-547.

409 22 Bryant AH, Spencer-Harty S, Owens SE, Jones RH, Thornton CA: Interleukin 4 and interleukin
410 13 downregulate the lipopolysaccharide-mediated inflammatory response by human gestation-
411 associated tissues. Biol Reprod 2017

412 23 Brooks MN, Rajaram MV, Azad AK, Amer AO, Valdivia-Arenas MA, Park JH, Nunez G,
413 Schlesinger LS: Nod2 controls the nature of the inflammatory response and subsequent fate of
414 mycobacterium tuberculosis and m. Bovis bcg in human macrophages. Cell Microbiol 2011;13:402-
415 418.

416 24 Juarez E, Carranza C, Hernandez-Sanchez F, Leon-Contreras JC, Hernandez-Pando R,
417 Escobedo D, Torres M, Sada E: Nod2 enhances the innate response of alveolar macrophages to
418 mycobacterium tuberculosis in humans. Eur J Immunol 2012;42:880-889.

419 25 Kühl AA, Erben U, Kredel LI, Siegmund B: Diversity of intestinal macrophages in inflammatory
420 bowel diseases. Frontiers in Immunology 2015;6:613.

421 26 Faustin B, Lartigue L, Bruey J-M, Luciano F, Sergienko E, Bailly-Maitre B, Volkmann N, Hanein
422 D, Rouiller I, Reed JC: Reconstituted nalp1 inflammasome reveals two-step mechanism of caspase-1
423 activation. Molecular cell 2007;25:713-724.

424 27 Hedl M, Abraham C: Distinct roles for nod2 protein and autocrine interleukin-1beta in
425 muramyl dipeptide-induced mitogen-activated protein kinase activation and cytokine secretion in
426 human macrophages. J Biol Chem 2011;286:26440-26449.

427 28 Prutsch N, Fock V, Haslinger P, Haider S, Fiala C, Pollheimer J, Knöfler M: The role of
428 interleukin-1β in human trophoblast motility. Placenta 2012;33:696-703.

429 29 Trautman MS, Collmer D, Edwin SS, White W, Mitchell MD, Dudley DJ: Expression of
430 interleukin-10 in human gestational tissues. J Soc Gynecol Investig 1997;4:247-253.

431 30 Han S, Jerome JA, Gregory AD, Mallampalli RK: Cigarette smoke destabilizes nlrp3 protein by
432 promoting its ubiquitination. Respiratory Research 2017;18:2.

433 31 Vandanmagsar B, Youm Y-H, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E,
434 Stephens JM, Dixit VD: The nalp3/nlrp3 inflammasome instigates obesity-induced autoinflammation
435 and insulin resistance. Nature medicine 2011;17:179-188.

436 32 Liu LF, Shen WJ, Ueno M, Patel S, Azhar S, Kraemer FB: Age-related modulation of the effects
437 of obesity on gene expression profiles of mouse bone marrow and epididymal adipocytes. PLoS One
438 2013;8:e72367.

439 33 Aye ILMH, Lager S, Ramirez VI, Gaccioli F, Dudley DJ, Jansson T, Powell TL: Increasing
440 maternal body mass index is associated with systemic inflammation in the mother and the activation
441 of distinct placental inflammatory pathways. Biology of Reproduction 2014;90:129.

442 34 Pantham P, Aye ILMH, Powell TL: Inflammation in maternal obesity and gestational diabetes
443 mellitus. Placenta 2015;36:709-715.

444 35 Romero R, Xu Y, Plazyo O, Chaemsaithong P, Chaiworapongsa T, Unkel R, Than NG, Chiang
445 PJ, Dong Z, Xu Z, Tarca AL, Abrahams VM, Hassan SS, Yeo L, Gomez-Lopez N: A role for the
446 inflammasome in spontaneous labor at term. Am J Reprod Immunol 2016

447 36 Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R, Humblin E, Hamman A,
448 Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Vegran F, Ghiringhelli F: The receptor nlrp3 is
449 a transcriptional regulator of th2 differentiation. Nat Immunol 2015;16:859-870.

450 37 Chaouat G: Regulation of t-cell activities at the feto-placental interface--by placenta? Am J
451 Reprod Immunol 1999;42:199-204.

452 38 Maneta E, Warren AY, Hay DP, Khan RN: Caspase-1-mediated cytokine release from
453 gestational tissues, placental, and cord blood. Frontiers in Physiology 2015;6:186.

454 39 Yin Y, Yan Y, Jiang X, Mai J, Chen NC, Wang H, Yang XF: Inflammasomes are differentially
455 expressed in cardiovascular and other tissues. International journal of immunopathology and
456 pharmacology 2009;22:311-322.

457 40 Man SM, Kanneganti T-D: Regulation of inflammasome activation. Immunological Reviews
458 2015;265:6-21.

459 41 Nadeau-Vallee M, Obari D, Quiniou C, Lubell WD, Olson DM, Girard S, Chemtob S: A critical
460 role of interleukin-1 in preterm labor. Cytokine Growth Factor Rev 2016;28:37-51.

461

462

463 **Table Legends**

464 **Table 1.** Sequences and optimum conditions for each pair of NOD-like receptor (NLR) primers used
465 for RT-PCR.

466

467 **Figure Legends**

468 **Figure 1. Gene Expression of NLRs by term non-laboured gestation-associated tissues.** RT-PCR
469 for NOD1, NOD2, NLRP3, NLRC4, NLRX1, NLRP1 and NAIP. Three representative samples of 5
470 are shown. Human spleen (S) was used as a positive control and UBE2D2 was used as a
471 housekeeping gene. L = 100 base pair ladder and the negative control (-ve) was with water replacing
472 cDNA in the reaction mix.

473 **Figure 2. Protein expression of NOD1 and NOD2 in human gestation-associated tissues.**

474 Immunolocalisation of NOD1 and NOD2 in placenta and fetal membranes. Negative (isotype match)
475 and positive (NOD1; tonsil and NOD2; colon) controls are also displayed. A representative example
476 of 7 is shown.

477

478 **Figure 3. Functional response of human gestation-associated tissues to NOD1 and NOD2**
479 **agonists.** NOD1/2 agonist induced cytokine response by term non-laboured placenta, choriodecidua
480 and amnion. IL-6, IL-8, IL-10 and IL-1β production (mean ± SEM) by the (A) placenta, (B)
481 choriodecidua, and (C) amnion following stimulation with 10 μg/ml Tri-DAP or MDP (n=6).
482 Statistically significant differences compared to unstimulated control are shown: * $p < 0.05$, **
483 $p < 0.01$, *** $p < 0.001$.

484

485 **Figure 4. Expression and functional response of NLRP3 in human gestation-associated tissues.**
486 (A) Immunolocalisation of NLRP3 in placenta and fetal membranes. Negative (isotype match) and

487 positive (tonsil) controls are also displayed. Representative examples of 7 are shown; placenta 1 is
488 from a woman of normal weight woman; placenta 2 is form a morbidly obese woman. (B-D)
489 Nigericin-induced IL-1β (mean ± SEM) response by term non-laboured (B) placenta, (C)
490 choriodecidua and (D) amnion. Statistically significant differences compared to unstimulated control
491 are shown: * $p < 0.05$, ** $p < 0.01$.

492

493 **Figure 5. Caspase-1 is required for NLR-induced IL-1β production by gestation-associated**
494 **tissues.** IL-1β production from explants of (A & D) placenta, (B & E) choriodecidua and (C & F)
495 amnion in response to Tri-DAP, MDP (A-C) or nigericin (D-F) pre-treated for 30 minutes with
496 caspase-1 inhibitor (Z-WEHD-FMK; 5 µM) or vehicle control (n=3). Statistically significant
497 differences compared to unstimulated control are shown: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p <$
498 0.0001.

499

500 **Supplementary Figure Legends**

501

502 **Figure S1. Immunolocalisation of NLRP3 in placenta is negatively correlated with body mass**
503 **index.**

504 Immunohistochemical staining for NLRP3 performed on formalin fixed, paraffin embedded sections
505 (4 µm) of placenta using mouse monoclonal anti-NLRP3 (10 µg/ml; Abcam, USA).

506

507

508

509

TABLE 1

Gene		Primer	Mg^{2+} Conc (nM)	Annealing Temp (°C)	Fr Si
NOD1	***F***	5' AGGCTGAGTACCATGGGCTA	2	66	
	R	5' GCCCGTTTAGTCACCCTTCA			
NOD2	***F***	5' CAGGCAGCACAGGTCAGCCC	2	71	
	R	5' GTTGTGCGGCTCGGCCTTCT			
NLRP1	***F***	5' ATACGAAGCCTTTGGGGACT	3	65	
	R	5' CACCGCTTCTCTCATCACAA			
NLRP3	***F***	5' ACCGGAGCCAGCAGGAGAGG	1.5	71	
	R	5' GAAGGCTGCCCTGGCTTGGG			
NLRC4	***F***	5' GCCTCAGGCTGCAAATAAAG	2	68	
	R	5' CCAAGCTGTCAGTCAGACCA			
NLRX1	***F***	5' GCTCCATGGCTTAGAGCATC	1.5	62	
	R	5' ACGTACTTGCTGGGGATACG			
NAIP	***F***	5' TTCTTGCCCTGAAAACTGCT	3	66	

	R	5' CGTATTGGGAAGTGGATGCT		
UBE2D2	***F***	5' GATCACAGTGGTCTCCAGCA	3nM	65°C
	R	5' TCCATTCCCGAGCTATTCTG		

Figure 1

L S -ve P P P C C C A A A

NOD1

NOD2

NLRP3

NLRC4

NLRX1

NLRP1

NAIP

UBE2D2

Placenta - NOD1
50 µm
Placenta - NOD2
50 µm
Placenta - Mouse IgG2
50 µm
Placenta - Rabbit IgG
50 µm
FM - NOD1
50 µm
FM - NOD2
50 µm
FM - Mouse IgG2
50 µm
FM - Rabbit IgG
50 µm
Tonsil - NOD1
50 µm
Colon - NOD2
50 µm

A









B









C









A



B



C



D





A
IL-1β pg/ml
2000
1500
1000
500
0
*
**
***
****
****
***
Vehicle
Z-WEHD-FMK
Tri-DAP
MDP



B
IL-1β pg/ml
1000
800
600
400
200
0
**
**
****
***
**
**
Vehicle
Z-WEHD-FMK
Tri-DAP
MDP



C
IL-1β pg/ml
200
150
100
50
0
Vehicle
Z-WEHD-FMK
Tri-DAP
MDP



D
IL-1β ng/ml
100
80
60
40
20
0
**
*
**
*
*
*
Vehicle
Z-WEHD-FMK
Nigericin
LPS



E
IL-1β ng/ml
150
100
50
0
***
****
****
****
**
*
*
Vehicle
Z-WEHD-FMK
Nigericin
LPS



F
IL-1β pg/ml
2000
1500
1000
500
0
Vehicle
Z-WEHD-FMK
Nigericin
LPS

Supplementary Figure 1